IBB240830P140500
- 0.05
- -0.18-78.26%
iShares Biotechnology ETF Newsroom
Moderna Price Target Announced at $82.00/Share by HSBC
Moderna Analyst Ratings
HSBC Upgrades Moderna(MRNA.US) to Hold Rating, Cuts Target Price to $82
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Alnylam Pharmaceuticals Price Target Raised to $280.00/Share From $248.00 by JP Morgan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Evercore ISI Raises Price Target on Argenx to $555 From $533, Keeps Outperform Rating
Regeneron Pharmaceuticals Analyst Ratings
What 25 Analyst Ratings Have To Say About Argenx
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $157
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
J.P. Morgan Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $640
Redburn Atlantic Adjusts Moderna Price Target to $102 From $117
Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Argus Research Maintains Moderna(MRNA.US) With Buy Rating
Argus Research Adjusts Moderna Price Target to $105 From $150, Buy Rating Maintained